



**Fig. S1. Intratumoral delivery of DC.IL32 promotes tumor infiltration by Type-1 CD8<sup>+</sup> T cells enriched in the VLA4<sup>+</sup>CXCR3<sup>+</sup>GRZA<sup>+</sup> phenotype.** **A.** Day 21 tumors were harvested from tumor-bearing mice treated as outlined in **Fig. 4** and CD8<sup>+</sup> T cells isolated by MACS from single-cell suspensions to a purity > 95% as outlined in Materials and Methods. Data are depicted in (mean ± SD) absolute numbers of cells bearing the indicated phenotype per gram of tumor tissue analyzed. In **B.**, CD8<sup>+</sup> T cells were then evaluated for co-expression of the indicated Type-1 markers by flow cytometry with data reported in absolute numbers as per gram tumor tissue analyzed. \*\*p < 0.05 versus DC.null or DC.ψ5 treatment groups.